Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Breast Neoplasms 9Multiple Myeloma 5Neoplasms 4Neoplasm Metastasis 4Kidney Neoplasms 3Giant Cell Tumor of Bone 3Smoldering Multiple Myeloma 2Prostatic Neoplasms 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer Metastatic 1Recurrence 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Osteoblastoma 1Neoplastic Cells, Circulating 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Inflammatory Breast Neoplasms 1Hypercalcemia 1Humoral Hypercalcemia Of Malignancy 1Hodgkin Disease 1Head and Neck Neoplasms 1Granuloma, Giant Cell 1

Interventions

Dexamethasone 11Lenalidomide 9Calcium Dobesilate 5carfilzomib 4daratumumab 3isatuximab 2iberdomide 2elotuzumab 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Leflunomide 2Denosumab 2selinexor 1pomalidomide 1piperine 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1Simvastatin 1Nivolumab 1Metformin 1Melphalan 1IPH-2101 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Cyclophosphamide 1Curcumin 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Smoldering Multiple Myeloma × Denosumab × Clear all
NCT03839459 2026-01-28

Denosumab for Smoldering Multiple Myeloma

University of Rochester

Phase 2 Completed
20 enrolled 8 charts
Plasma cell

Smoldering Multiple Myeloma

NCT03792763 2025-02-11

DEFENCE

Arbeitsgemeinschaft medikamentoese Tumortherapie

Phase 2 Completed
8 enrolled
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡